- MongoDB nearly tripled the adjusted EPS expectation in fiscal Q1.
- MDB stock completely closed the gap from September 1, 2022.
- Atlas platform, which accounts for two-thirds of revenue, increased 40% YoY.
- MongoDB added 2,300 customers in Q1, the most in two years.
MongoDB (MDB), a company that provides a cloud database-as-a-service platform to corporations worldwide, surprised the market late Thursday with a strong showing in its fiscal first-quarter earnings results. MDB shot up 27% in Friday’s premarket, adding about $6 billion in market cap to the tech firm.
MongoDB stock news: Guidance swings higher
Wall Street analysts had placed their consensus for $0.19, but instead MongoDB brought home nearly three times as much at $0.56 per share. Revenue of $368 million grew 29% YoY and beat the analyst consensus by $21 million.
MongoDB’s main product, its Atlas platform, saw revenue rise 40% YoY as the company added 2,300 customers during the quarter – its highest in two years. It now has 43,100 customers.
The outlook is what really drove market demand however. MongoDB CEO Dev Ittycheria guided for next quarter revenue at a midpoint of $390 million. Prior forecasts had average just below $361 million. Ittycheria also said Q2 adjusted EPS would arrive between $0.43 and $0.46 versus consensus from analysts for $0.14.
For the full year, MongoDB’s management is expecting revenue of $1.532 billion, while consensus had been $1.510 billion. The consensus estimate for full-year adjusted EPS at $1.04 was easily surpassed by Ittycheria’s $1.49 midpoint guide.
“The shift to AI will favor modern platforms that offer a rich and sophisticated set of capabilities, delivered in a performance and scalable way,” said Ittycheria on the earnings call. “We are observing an emerging trend where customers are increasingly choosing Atlas as a platform to build and run new AI applications. For example, in Q1, more than 200 of the new Atlas customers were [artificial intelligence] or [machine learning] companies.”
MongoDB stock forecast
MongoDB stock was already telling traders it was a buy when the daily chart featured a Golden Cross on May 10. This is when the 50-day moving average crosses above its 200-day counterpart. Although the 200-day was rising at the time of the cross (ideally it should be falling too), it may still be a bullish sign for the stock. MDB stock has been in an uptrend since last November, but this current earnings rally is still a bit surprising.
MDB gobbled up the gap down from September 1 of last year and is now approaching resistance from August 2022 at $390. Above that point there are few bull targets until one reaches the $460 double-top from spring 2020.
MDB daily chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.